The stock of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) hit a new 52-week high and has $5.75 target or 151.00% above today’s $2.29 share price. The 6 months bullish chart indicates low risk for the $176.87M company. The 1-year high was reported on Oct, 17 by Barchart.com. If the $5.75 price target is reached, the company will be worth $267.07M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 24.75M shares traded hands or 2302.91% up from the average. ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has risen 83.18% since March 14, 2016 and is uptrending. It has outperformed by 77.57% the S&P500.
According to Zacks Investment Research, “ContraVir Pharmaceuticals Inc. is a biopharmaceutical company. The company is involved in the discovery and development of antiviral therapies. ContraVir Pharmaceuticals Inc. is headquartered in Edison, New Jersey.”
More recent ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) news were published by: 247Wallst.com which released: “How ContraVir Pharma Won Big on Its HBV Interim Results” on October 13, 2016. Also Prnewswire.com published the news titled: “ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., to Board of Directors” on September 21, 2016. Prnewswire.com‘s news article titled: “ContraVir Completes Merger with Ciclofilin Pharmaceuticals” with publication date: June 13, 2016 was also an interesting one.
CTRV Company Profile
ContraVir Pharmaceuticals, Inc., incorporated on May 15, 2013, is a biopharmaceutical company. The Firm focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Firm develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Firm is also developing an antiviral asset, FV-100.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.